Incidences of sAML-like gene mutations. (A) sAML-like gene mutation in the whole population of 471 patients analyzed. (B) sAML-like gene mutation in the subset of 129 patients with ELN-2017 intermediate-risk AML who were analyzed. Of note, none of these patients had AML with ASXL1 and/or RUNX1 gene mutation, which are 2 criteria for adverse-risk AML in this classification. In these patients, the incidence of sAML-like mutations was not higher in patients with chromosomal abnormalities compared with those with a normal karyotype (41% vs 36%; P = .59). sAML is clinically defined as patients with prior myelodysplastic syndromes or chronic myelomonocytic leukemia (N = 74 patients). (C) Incidences of NPM1, FLT3, IDH1/2, and DNMT3A gene mutations in ELN-2017 intermediate-risk AML analyzed, according to the presence (n = 49) or absence (n = 80) of sAML-like gene mutations. As shown, FLT3-ITD mutations were more frequently observed in patients without sAML-like mutations, whereas IDH2 mutations were more frequently observed in those with sAML-like mutations. Of note, among these IDH2 gene mutations, the incidence of the poor-prognosis IDH2 R172 mutation was 6/49 vs 9/80 (P = .54).